Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocugen (OCGN) Gains from Sales and Divestitures (2015 - 2017)

Ocugen posted quarterly Gains from Sales and Divestitures of $1889.0 for Q4 2017, down 42.77% year-on-year from $3301.0 in Q4 2016, and little changed on a QoQ basis from $1889.0 in Q3 2017.

Ocugen (OCGN) has 3 years of Gains from Sales and Divestitures data on file, last reported at $1889.0 in Q4 2017.

  • For the quarter ending Q4 2017, Gains from Sales and Divestitures fell 42.77% year-over-year to $1889.0; the trailing twelve-month figure through Dec 2017 stood at $1889.0 (down 42.77% YoY), and the FY2017 full-year result was $1889.0, down 42.77% from the prior year.
  • Gains from Sales and Divestitures for Q4 2017 stood at $1889.0, roughly flat from $1889.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $3303.0 in Q4 2015 and bottomed at $1889.0 in Q2 2015.
  • The 3-year median for Gains from Sales and Divestitures is $1889.0 (2015), against an average of $2203.0.
  • The widest annual swing landed in 2016, when Gains from Sales and Divestitures changed 0.0%; it then plunged 42.77% in 2017.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $3303.0 in 2015, then retreated by 0.06% to $3301.0 in 2016, then sank by 42.77% to $1889.0 in 2017.
  • The last three Gains from Sales and Divestitures figures came in at $1889.0 (Q4 2017), $1889.0 (Q3 2017), and $1889.0 (Q2 2017), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Ocugen 452.01 Mn 452.01 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2017 1,889.00
Dec 31, 2017 1,889.00
Sep 30, 2017 1,889.00
Sep 30, 2017 1,889.00
Jun 30, 2017 1,889.00
Jun 30, 2017 1,889.00
Dec 31, 2016 3,301.00
Dec 31, 2016 3,301.00
Sep 30, 2016 1,889.00
Sep 30, 2016 1,889.00
Jun 30, 2016 1,889.00
Jun 30, 2016 1,889.00
Dec 31, 2015 3,303.00
Dec 31, 2015 3,303.00
Sep 30, 2015 1,889.00
Sep 30, 2015 1,889.00
Jun 30, 2015 1,889.00
Jun 30, 2015 1,889.00